Ways to improve the results of conservative therapy of malignant tumors of the head and neck organs. Part I. The current state of the issue (review)

Abstract

The review analyzes the results of conservative therapy of patients with the head and neck cancer. Despite the use of modern radiation and drug technologies, the results of treatment of locally advanced forms of head and neck cancers and relapses are not satisfactory. The most effective is the simultaneous use of modified radiation and chemotherapy regimens. However, the implementation of the treatment plan with this method is limited to the development of pronounced early and late toxic effects on normal tissues and organs. The radiosensitizing effect of targeted therapy was also analyzed.

Keywords

squamous cell carcinoma of the head and neck organs / radiation therapy / chemoradiotherapy / targeted therapy

References

[1] SEER Cancer Statistics Review (CSR) 1975–2015 [internet] [updated 10 Sep 2018]. Available from: https://seer.cancer.gov/archive/csr/1975_2015/

[2] SEER Cancer Statistics Review (CSR) 1975–2015 [internet] [updated September 10, 2018]. Доступ по ссылке: https://seer.cancer.gov/archive/csr/1975_2015/

[3] The state of cancer care for the population of Russia in 2022. Kaprin AD, Starinsky VV, Shakhzadova AO, editors; Moscow: MNIOI named PA. Herzen — branch of NMRRC; 2023. 239 p. (In Russ).

[4] Состояние онкологической помощи населению России в 2022 году/под редакцией Каприна А.Д., Старинского В.В., Шахзадовой А.О. Москва: МНИОИ им П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2023. 239 с.

[5] Grégoire V, Lefebvre JL, Licitra L, Felip E; EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v184–186. doi: 10.1093/annonc/mdq185

[6] Gregoire V., Lefebvre J.L., Licitra L., et al. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann Oncol. 2010. Vol. 21, Suppl. 5. P. 184–186. doi: 10.1093/annonc/mdq185

[7] Lefebvre JL, Lartigau E, Kara A, Sarini J. Oral Cavity, Pharynx and Larynx Cancer. In: Prognostic Factors in Cancer. Head and Neck Tumors; New York: A. John Wiley and Sons, Inc. 2001. P. 151–166. doi: 10.1002/0471463736.tnmp11

[8] Lefebvre J.L., Lartigau E., Kara A., Sarini J. Oral Cavity, Pharynx and Larynx Cancer. In: Prognostic Factors in Cancer. Head and Neck Tumors; New York: A. John Wiley and Sons, Inc. 2001. P. 151–166. doi: 10.1002/0471463736.tnmp11

[9] Laramore GE, Coltrera MD, Karen JH. Tumors of Head and Neck. In: Cliniсal Oncology. 8th edition. Rubin Ph, editor. Philadelphia: W.B. Saunders Co., 2001. P. 405–461.

[10] Laramore G.E., Coltrera M.D., Karen J.H. Tumors of Head and Neck. In: Cliniсal Oncology. 8th edition. Rubin Ph., editor. Philadelphia: W.B. Saunders Co., 2001. P. 405–461.

[11] Parkhomenko LB, Krutilina NI. Results of chemoradiotherapy with altered fractionation for locally advanced larynx cancer. Oncology Journal. 2021;15(1(57)):50–56. EDN: VXFUTM

[12] Пархоменко Л.Б., Крутилина Н.И. Результаты химиолучевого лечения с нетрадиционным фракционированием местнораспространенного рака гортани // Онкологический журнал. 2021. Т. 15, № 1(57). С. 50–56. EDN: VXFUTM

[13] Schiff BA. Overview of Head and Neck Tumors. MSD Handbook. Professional version. Reviewed/Revised Dec 2022. Available from: https://www.msdmanuals.com/ru

[14] Schiff B.A. Обзор опухолей головы и шеи. Справочник MSD. Профессиональная версия. Проверено/пересмотрено дек 2022. Доступ по ссылке: https://www.msdmanuals.com/ru

[15] Oral Cavity Cancer. Clinical Practice Guideline HN-002 – Version 2. Clinical Effective December, 2023]. Available from: www.ahs.ca/guru

[16] Oral Cavity Cancer. In: Clinical Practice Guideline HN-002 – Version 2. Clinical Effective Date [December, 2023]. Доступ по ссылке: www.ahs.ca/guru

[17] Laskar SG, Agarwal JP, Srinivas C, Dinshaw KA. Radiotherapeutic management of locally advanced head and neck cancer. Expert Rev Anticancer Ther. 2006;6:405–417. doi: 10.1586/14737140.6.3.405

[18] Laskar S.G, Agarwal J.P., Srinivas C., Dinshaw K.A. Radiotherapeutic management of locally advanced head and neck cancer // Expert Rev Anticancer Ther. 2006. Vol. 6. P. 405–417. doi: 10.1586/14737140.6.3.405

[19] Fan KH, Chen YC, Lin CY, et al. Postoperative radiotherapy with or without concurrent chemotherapy for oral squamous cell carcinoma in patients with three or more minor risk factors: a propensity score matching analysis. Radiat Oncol. 2017;12(1):184. doi: 10.1186/s13014-017-0910-0

[20] Fan K.H, Chen Y.C, Lin C.Y., et al. Postoperative radiotherapy with or without concurrent chemotherapy for oral squamous cell carcinoma in patients with three or more minor risk factors: a propensity score matching analysis // Radiat Oncol. 2017. Vol. 12, N. 1. P. 184. doi: 10.1186/s13014-017-0910-0

[21] Huang SH, O´Sullivan B. Oral cancer: Current role of radiotherapy and chemotherapy. Med Oral Patol Oral Cir Bucal. 2013;18(2):e233–240. doi: 10.4317/medoral.18772

[22] Huang S.H., O´Sullivan B. Oral cancer: Current role of radiotherapy and chemotherapy // Med Oral Patol Oral Cir Bucal. 2013. Vol. 18, N. 2. P. e233–240. doi: 10.4317/medoral.18772

[23] Gevorkov AR, Boiko AV, Zavalishina LE, et al. Separate conservative and combined treatment for tongue cancer. P.A. Herzen Journal of Oncology. 2014;4:25–29. EDN: TAIZSJ

[24] Геворков А.Р., Бойко А.В., Завалишина Л.Э., и др. Самостоятельное консервативное и комбинированное лечение рака языка // Онкология. Журнал им. П.А. Герцена, 2014. № 4. С. 25–29. EDN: TAIZSJ

[25] Donald PJ. The difficult case in head and neck cancer surgery. New York: Thieme Medical Publishers; 2009. Р. 541. doi: 10.1055/b-002-59197

[26] Donald P.J. The difficult case in head and neck cancer surgery. New York: Thieme Medical Publishers, 2009. Р. 541. doi: 10.1055/b-002-59197

[27] Leemans R. Strategies for non-resectable tumors; 3rd trends in head and neck oncology. Rome; 2011.

[28] Leemans R. Strategies for non-resectable tumors. 3rd trends in head and neck oncology. Rome, 2011.

[29] Hassanein KA, Musgrove BT, Bradbury E. Psychological outcome of patients following treatment of oral cancer and its relation with functional status and coping mechanisms. J Craniomaxillofac Surg. 2005;33(6):404–409. doi: 10.1016/j.jcms.2005.05.005

[30] Hassanein K.A., Musgrove B.T., Bradbury E. Psychological outcome of patients following treatment of oral cancer and its relation with functional status and coping mechanisms // J Craniomaxillofac Surg. 2005. Vol. 33, N. 6. P. 404–409. doi: 10.1016/j.jcms.2005.05.005

[31] Hasegawa T, Yatagai N, Furukawa T, et al. The prospective evaluation and risk factors of dysphagia after surgery in patients with oral cancer. J Otolaryngol Head & Neck Surg. 2021;4. doi: 10.1186/s40463-020-00479-6

[32] Hasegawa T., Yatagai N., Furukawa T., et al. The prospective evaluation and risk factors of dysphagia after surgery in patients with oral cancer // J Otolaryngol Head & Neck Surg. 2021. Vol. 4. doi: 10.1186/s40463-020-00479-6

[33] Nagy J, Braunitzer G, Antal M, et al. Quality of life in head and neck cancer patients after tumor therapy and subsequent rehabilitation: an exploratory study. Qual Life Res. 2014;23(1):135–143. doi: 10.1007/s11136-013-0446-1

[34] Nagy J., Braunitzer G., Antal M., et al. Quality of life in head and neck cancer patients after tumor therapy and subsequent rehabilitation: an exploratory study // Qual Life Res. 2014. Vol. 23, N. 1. P. 135–143. doi: 10.1007/s11136-013-0446-1

[35] Kropotov MA. Organ-preserving and reconstructive operations on the lower jaw in the combined treatment of cancer of the oral mucosa [dissertation]. Moscow; 2004. (In Russ). EDN: NPXTZJ

[36] Кропотов М.А. Органосохраняющие и реконструктивные операции на нижней челюсти в комбинированном лечении рака слизистой оболочки полости рта: дис… д-ра. мед. наук. Москва, 2004. EDN: NPXTZJ

[37] Kropotov MA, Epikhina AV, Udintsov DK, Il’kaev КD. Oropharyngeal cancer: the aspects of surgical treatment. Bulletin of Otorhinolaryngology. 2013;6:13–17. EDN: NYACZZ

[38] Кропотов М.А., Епихина А.В., Удинцов Д.К., Илькаев К.Д. Рак ротоглотки: аспекты хирургического лечения // Вестник оториноларингологии. 2013. № 6. С. 13–17. EDN: NYACZZ

[39] Rebrikova IV, Polyakov AP. Salvage surgery in the treatment of patients with recurrent squamous cell carcinoma of the oral cavity. P.A. Herzen Journal of Oncology. 2022;11(1):60–63. doi: 10.17116/onkolog20221101160

[40] Ребрикова И.В., Поляков А.П. Спасительная хирургия в лечении пациентов с рецидивным плоскоклеточным раком полости рта // Онкология. Журнал им. П.А. Герцена. 2022. Т. 11, № 1. С. 60–63. doi: 10.17116/onkolog20221101160

[41] Li Y, Jiang Y, Qiu B, et al. Current radiotherapy for recurrent head and neck cancer in the modern era: a state of the art review. J Trans Med. 2022;20:566. doi: 10.1186/s12967-022-03774-0

[42] Li Y., Jiang Y., Qiu B., et al. Current radiotherapy for recurrent head and neck cancer in the modern era: a state of the art review // J Trans Med. 2022. Vol. 20. P. 566. doi: 10.1186/s12967-022-03774-0

[43] Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008;30:281–288. doi: 10.1002/hed.20697

[44] Spencer S.A., Harris J., Wheeler R.H., et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck // Head Neck. 2008. Vol. 30. P. 281–288. doi: 10.1002/hed.20697

[45] Langer CJ, Harris J, Horwitz EM, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol. 2007;25:4800–4805. doi: 10.1200/JCO.2006.07.9194

[46] Langer CJ, Harris J, Horwitz EM, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911 // J Clin Oncol. 2007. Vol. 25. P. 4800–4805. doi: 10.1200/JCO.2006.07.9194

[47] Kaprin AD, Boiko AV, Gevorkov AR, Bolotina LV. The current state of radiotherapy in patients with oropharyngeal squamous cell carcinoma. A radiation therapist’s view. P.A. Herzen Journal of Oncology. 2017;6(4):4–8. doi: 10.17116/onkolog2017644-8

[48] Каприн А.Д., Бойко А.В., Геворков А.Р., Болотина Л.В. Современное состояние проблемы лучевой терапии больных плоскоклеточным раком орофарингеальной области. Взгляд радиотерапевта // Онкология. Журнал им. П.А. Герцена, 2017. Т. 6, № 4. С. 4–8. doi: 10.17116/onkolog2017644-8

[49] Boyko AV, Gevorkov AR, Semin DYu. Oropharyngeal cancer. In: National guidelines: Therapeutic radiology. Kaprin AD, Mardinsky YuS, editors. Moscow: GEOTAR-Media; 2018. P. 218–271.

[50] Бойко А.В., Геворков А.Р., Семин Д.Ю. Рак орофарингеальной области. Национальное руководство: Терапевтическая радиология/Под ред.: Каприна А.Д., Мардынского Ю.С. Москва. Издательская группа ГЭОТАР-Медиа, 2018. С. 218–271.

[51] Carvalho AL; Magrin J, Kowalski LP. Sites of recurrence in oral and oropharyngeal cancers according to the treatment approach. Oral Diseases. 2003;9(3):112–118. doi: 10.1034/j.1601-0825.2003.01750.x

[52] Carvalho A.L., Magrin J., Kowalski L.P. Sites of recurrence in oral and oropharyngeal cancers according to the treatment approach // Oral Diseases. 2003. Vol. 9, N. 3. P. 112–118. doi: 10.1034/j.1601-0825.2003.01750.x

[53] Horiot JC, Fur RL, N’Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngecal carcinoma final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother. Oncol. 1992;25(4):231–241. doi: 10.1016/0167-8140(92)90242-m

[54] Horiot J.C., Le Fur R., N’Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngecal carcinoma final analysis of a randomized trial of the EORTC cooperative group of radiotherapy // Radiother. Oncol. 1992. Vol. 25, N. 4. P. 231–241. doi: 10.1016/0167-8140(92)90242-m

[55] Skladowski K, Maciejewski B, Golen M, et al. Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial. Int J Radiat Oncol Biol Phys. 2006;66(3):706-13. doi: 10.1016/j.ijrobp.2006.05.026

[56] Skladowski K., Maciejewski B., Golen M., et al. Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial // Int J Radiat Oncol Biol Phys. 2006. Vol. 66, N. 3. P. 706–713. doi: 10.1016/j.ijrobp.2006.05.026

[57] Zhu B, Kou C, Bai W, et al. Accelerated Hyperfractionated Radiotherapy versus Conventional Fractionation Radiotherapy for Head and Neck Cancer: A Meta-Analysis of Randomized Controlled Trials. J Oncol. 2019;2019:7634746. doi: 10.1155/2019/7634746

[58] Zhu B., Kou C., Bai W., et al. Accelerated Hyperfractionated Radiotherapy versus Conventional Fractionation Radiotherapy for Head and Neck Cancer: A Meta-Analysis of Randomized Controlled Trials. J Oncol. 2019. Vol. 2019. P. 7634746. doi: 10.1155/2019/7634746

[59] Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003;362(9388):933–940. doi: 10.1016/s0140-6736(03)14361-9

[60] Overgaard J., Hansen H.S., Specht L., et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial // Lancet. 2003. Vol. 362, N. 9388. P. 933–940. doi: 10.1016/s0140-6736(03)14361-9

[61] Overgaard J, Mohanti BK, Begum N, et al. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomized, multicentre trial. Lancet Oncol. 2010;11(6):553–560. doi: 10.1016/S1470-2045(10)70072-3

[62] Overgaard J., Mohanti B.K., Begum N., et al. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomized, multicentre trial // Lancet Oncol. 2010. Vol. 11. N. 6. P. 553–560. doi: 10.1016/S1470-2045(10)70072-3

[63] Bourhis J, Overgaard J, Audry H, Ang KK, et al; Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368(9538):843–854. doi: 10.1016/S0140-6736(06)69121-6

[64] Bourhis J., Overgaard J., Audry H., et al; Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis // Lancet. 2006. Vol. 368, N. 9538. P. 843–854. doi: 10.1016/S0140-6736(06)69121-6

[65] Lacas B, Bourhis J, Overgaard J, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017;18(9):1221–1237. doi: 10.1016/S1470-2045(17)30458-8

[66] Lacas B., Bourhis J., Overgaard J., et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis // Lancet Oncol. 2017. Vol. 18, N. 9. P. 1221–1237. doi: 10.1016/S1470-2045(17)30458-8

[67] Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48(1):7–16. doi: 10.1016/s0360-3016(00)00663-5

[68] Fu K.K., Pajak T.F., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003 // Int J Radiat Oncol Biol Phys. 2000. Vol. 48, N. 1. P. 7–16. doi: 10.1016/s0360-3016(00)00663-5

[69] Hliniak A, Gwiazdowska B, Szutkowski Z, et al. A multicentre randomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer: influence of a 1 week shortening overall time. Radiother Oncol. 2002;62(1):1-10. doi: 10.1016/s0167-8140(01)00494-7

[70] Hliniak A., Gwiazdowska B., Szutkowski Z., et al. A multicentre randomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer: influence of a 1 week shortening overall time // Radiother Oncol. 2002. Vol. 62, N. 1. P. 1-10. doi: 10.1016/s0167-8140(01)00494-7

[71] Ghosh–Laskar S, Kalyani N, Gupta T, et al. Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial. Head Neck. 2016;38(2):202–207. doi: 10.1002/hed.23865

[72] Ghosh–Laskar S., Kalyani N., Gupta T., et al. Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial // Head Neck. 2016. Vol. 38, N. 2. P. 202–207. doi: 10.1002/hed.23865

[73] Dische S, Saunders M, Barrett A, et al. A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 1997;44(2):123–136. doi: 10.1016/S0167-8140(97)00094-7

[74] Dische S., Saunders M., Barrett A., et al. A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer // Radiother Oncol. 1997. Vol. 44, N. 2. P. 123–136. doi: 10.1016/S0167-8140(97)00094-7

[75] Bogaert Van den W, Schueren van der E, Horiot JС, et al. Early results of the EORTC randomized clinical trial on multiple fractions per day and misonidazole in advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 1986;12(4):587–591. doi: 10.1016/0360-3016(86)90067-2

[76] Bogaert Van den W., Schueren van der E., Horiot J.С., et al. Early results of the EORTC randomized clinical trial on multiple fractions per day and misonidazole in advanced head and neck cancer // Int J Radiat Oncol Biol Phys. 1986. Vol. 12, N. 4. P. 587–591. doi: 10.1016/0360-3016(86)90067-2

[77] Marcial VA, Pajak TF, Chang С, et al. Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Oncology Group (RTOG). Int J Radial Oncol Biol Phys. 1987;13(1):41–47. doi: 10.1016/0360-3016(87)90258-6

[78] Marcial V A., Pajak T.F., Chang С., et al. Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Oncology Group (RTOG) // Int J Radial Oncol Biol Phys. 1987. Vol. 13, N. 1. P. 41–47. doi: 10.1016/0360-3016(87)90258-6

[79] Jackson SM, Weir LM, Hay JH, et al. A randomized trial of accelerited versus conventional radiotherapy in head and neck cancers. Raidiother Oncol. 1997;43(1):39–46. doi: 10.1016/s0167-8140(97)01944-0

[80] Jackson S.M., Weir L.M., Hay J.H., et al. A randomized trial of accelerated versus conventional radiotherapy in head and neck cancers // Radiother. Oncol. 1997. Vol. 43, N. 1. P. 39–46. doi: 10.1016/s0167-8140(97)01944-0

[81] Kanaev SV. Radiation therapy of malignant tumors of the head and neck. Practical Oncology. 2003;4(1):15–24. (In Russ). EDN: QIKTAB

[82] Канаев С.В. Лучевая терапия злокачественных опухолей головы и шеи // Практическая онкология. 2003. Т. 4, № 1. С. 15–24. EDN: QIKTAB

[83] Zhang S, Zeng N, Yang J, He J, Zhu F, Liao W, Xiong M, Li Y. Advancements of radiotherapy for recurrent head and neck cancer in modern era. Radiat Oncol. 2023;18(1):166. doi: 10.1186/s13014-023-02342-0

[84] Zhang S., Zeng N., Yang J., et al. Advancements of radiotherapy for recurrent head and neck cancer in modern era // Radiat Oncol. 2023. Vol. 18, N. 1. P. 166. doi: 10.1186/s13014-023-02342-0

[85] Solodkiy VA, Panshin GA, Titova VA, et al. Relapse-free survival in patients with malignant tumors of the oral mucosa after multicomponent treatment. P.A. Herzen Journal of Oncology. 2022;11(4):5–11. doi: 10.17116/onkolog2022110415

[86] Солодкий В.А., Паньшин Г.А., Титова В.А., и др. Безрецидивная выживаемость пациентов со злокачественными опухолями слизистой оболочки полости рта после многокомпонентного лечения // Онкология. Журнал им. П.А. Герцена. 2022. Т. 11, № 4. С. 5–11. doi: 10.17116/onkolog2022110415

[87] Nevens D, Duprez F, Daisne JF, et al. Reduction of the dose of radiotherapy to the elective neck in head and neck squamous cell carcinoma; a randomized clinical trial. Effect on late toxicity and tumor control. Radiother Oncol. 2017;122(2):171–177. doi: 10.1016/j.radonc.2016.08.009

[88] Nevens D., Duprez F., Daisne JF., et al. Reduction of the dose of radiotherapy to the elective neck in head and neck squamous cell carcinoma; a randomized clinical trial. Effect on late toxicity and tumor control // Radiother Oncol. 2017. Vol. 122, N. 2. P. 171–177. doi: 10.1016/j.radonc.2016.08.009

[89] Gladilina IA, Shabanov MA. Radiation and chemoradiotherapy treatment of advanced oropharyngeal cancer. Moscow; 2001. 164 p. (In Russ).

[90] Гладилина И.А., Шабанов М.А. Лучевое и химиолучевое лечение распространенного рака ротоглотки. Москва, 2001. 164 с.

[91] Sokurenko VP. Rationale for the choice of radiation and chemoradiotherapy for patients with locally advanced cancer of the oropharynx and oral cavity stage III–IV [dissertation]. St. Petersburg; 2010. 45 p. (In Russ). EDN: QGVHDV

[92] Сокуренко В.П. Обоснование выбора лучевой и химиолучевой терапии больных местно-распространенным раком ротоглотки и полости рта III–IV стадии: автореф. дис. … докт. мед. наук. Санкт-Петербург, 2010. 45 с. EDN: QGVHDV

[93] Stukan AI, Murashko RA, Bodnya VN, et al. Topical issues of chemoradiotherapy for oropharyngeal squamous cell carcinoma: the efficiency and toxicity of chemotherapy regimens with the goal of radiomodification. P.A. Herzen Journal of Oncology. 2018;7(3):61–67. doi: 10.17116/onkolog20187361

[94] Стукань А.И., Мурашко Р.А., Бодня В.Н. и др. Актуальные вопросы химиолучевого лечения орофарингеальной плоскоклеточной карциномы: эффективность и токсичность режимов химиотерапии с целью радиомодификации // Онкология. Журнал им. П.А. Герцена. 2018. Т. 7, № 3. С. 61–67. doi: 10.17116/onkolog20187361

[95] Schüttrumpf L, Marschner S, Scheu K, et al. Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck — results from an unselected cohort of the clinical cooperation group “Personalized Radiotherapy in Head and Neck Cancer”. Radiat Oncol. 2020;15(1):7. doi: 10.1186/s13014-019-1452-4

[96] Schüttrumpf L., Marschner S., Scheu K., et al. Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck — results from an unselected cohort of the clinical cooperation group “Personalized Radiotherapy in Head and Neck Cancer” // Radiat Oncol. 2020. Vol. 15, N. 1. P. 7. doi: 10.1186/s13014-019-1452-4

[97] Müller von der Grün J, Martin D, Stöver T, et al. Chemoradiotherapy as Definitive Treatment for Elderly Patients with Head and Neck Cancer. Biomed Res Int. 2018;2018:3508795. doi: 10.1155/2018/3508795

[98] Müller von der Grün J., Martin D., Stöver T., et al. Chemoradiotherapy as Definitive Treatment for Elderly Patients with Head and Neck Cancer // Biomed Res Int. 2018. Vol. 2018. P. 3508795. doi: 10.1155/2018/3508795

[99] Chitapanarux I, Tharavichitkul E, Kamnerdsupaphon P, et al. Randomized phase III trial of concurrent chemoradiotherapy vs accelerated hyperfractionation radiotherapy in locally advanced head and neck cancer. J Radiat Res. 2013;54:1110–1117. doi: 10.1093/jrr/rrt054

[100] Chitapanarux I., Tharavichitkul E., Kamnerdsupaphon P., et al. Randomized phase III trial of concurrent chemoradiotherapy vs accelerated hyperfractionation radiotherapy in locally advanced head and neck cancer // J Radiat Res. 2013. Vol. 54. P. 1110–1117. doi: 10.1093/jrr/rrt054

[101] Semin DYu, Mardynsky YuS, Medvedev VS, et al. Immediate and long-term results of simultaneous chemoradiotherapy in non-traditional modes of fractionation in the treatment of patients with oropharyngeal squamous cell carcinoma. Problems in Oncology. 2013;59(6):725–730. EDN: RTUROH

[102] Семин Д.Ю., Мардынский Ю.С., Медведев В.С., и др. Непосредственные и отдаленные результаты одновременной химиолучевой терапии в режимах нетрадиционного фракционирования при лечении больных плоскоклеточным раком орофарингеальной области // Вопросы онкологии. 2013. Т. 59, № 6. С. 725–730. EDN: RTUROH

[103] Budach W, Hehr T, Budach V, et al. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006;6:28. doi: 10.1186/1471-2407-6-28

[104] Budach W., Hehr T., Budach V., et al. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck // BMC Cancer. 2006. Vol. 6. P. 28. doi: 10.1186/1471-2407-6-28

[105] Budach V, Stromberger C, Poettgen C, et al. Hyperfractionated Accelerated Radiation Therapy (HART) of 70.6 Gy With Concurrent 5-FU/Mitomycin C is Superior to HART of 77.6 Gy Alone in Locally Advanced Head and Neck Cancer: Long-term Results of the ARO 95–06 Randomized Phase III Trial. Int J Radiat Oncol. 2015;91(5):916–924. doi: 10.1016/j.ijrobp.2014.12.034

[106] Budach V., Stromberger C., Poettgen C., et al. Hyperfractionated Accelerated Radiation Therapy (HART) of 70.6 Gy With Concurrent 5-FU/Mitomycin C is Superior to HART of 77.6 Gy Alone in Locally Advanced Head and Neck Cancer: Long-term Results of the ARO 95–06 Randomized Phase III Trial // Int J Radiat Oncol. 2015. Vol. 91, N. 5. P. 916–924. doi: 10.1016/j.ijrobp.2014.12.034

[107] Petit C, Lacas B, Pignon JP, et al. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. Lancet Oncol. 2021;22(5):727–736. doi: 10.1016/S1470-2045(21)00076-0

[108] Petit C., Lacas B., Pignon J.P., et al. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis // Lancet Oncol. 2021. Vol. 22, N. 5. P. 727–736. doi: 10.1016/S1470-2045(21)00076-0

[109] Morris ZS, Mohindra P, Kruser TJ. Combined Chemoradiation Therapy in the Treatment of Squamous Cell. Carcinoma of the Head and Neck—An Evolving Paradigm. Oncology & Hematology Review (US). 2013;9(2):115–121. doi: 10.17925/OHR.2013.09.2.115

[110] Morris Z.S., Mohindra P., Kruser T.J. Combined Chemoradiation Therapy in the Treatment of Squamous Cell. Carcinoma of the Head and Neck—An Evolving Paradigm // Oncology & Hematology Review (US). 2013. Vol. 9, N. 2. P. 115–121. doi: 10.17925/OHR.2013.09.2.115

[111] Porceddu SV, Scotté F, Aapro M, et al. Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy. Front. Oncol. 2020;9:1522. doi: 10.3389/fonc.2019.01522

[112] Porceddu S.V., Scotté F., Aapro M., et al. Treating patients with locally advanced squamous cell carcinoma of the head and neck unsuitable to receive cisplatin-based therapy // Front Oncol. 2020, Vol. 9. P. 1522. doi: 10.3389/fonc.2019.01522

[113] Iyer NG, Tan DSW, Tan VKM, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer 2015;121(10):1599–1607. doi: 10.1002/cncr.29251 Erratum in: Cancer. 2015;121(19):3560. doi: 10.1002/cncr.29500

[114] Iyer N.G., Tan D.S.W., Tan V.K.M., et al. Randomized Trial Comparing Surgery and Adjuvant Radiotherapy Versus Concurrent Chemoradiotherapy in Patients With Advanced, Nonmetastatic Squamous Cell Carcinoma of the Head and Neck: 10-Year Update and Subset Analysis // Cancer 2015. Vol. 121, N. 10. P. 1599–1607. doi: 10.1002/cncr.29251 Erratum in: Cancer. 2015. Vol. 121, N. 19. P. 3560. doi: 10.1002/cncr.29500

[115] Bessell A, Glenny AM, Furness S, et al. Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. Cochrane Database Syst Rev. 2011;(9):CD006205. doi: 10.1002/14651858.CD006205.pub3. Update in: Cochrane Database Syst Rev. 2018;(12):CD006205. doi: 10.1002/14651858.CD006205.pub4

[116] Bessell A., Glenny A.M., Furness S., et al. Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment // Cochrane Database Syst Rev. 2011. N. 9. P. CD006205. doi: 10.1002/14651858.CD006205.pub3. Update in: Cochrane Database Syst Rev. 2018. N. 12. P. CD006205. doi: 10.1002/14651858.CD006205.pub4

[117] Chauhan A, Sehgal SA, Khurana A, et al. Is Accelerated Radiation Therapy an Answer where Concurrent Chemoradiation is not Feasible for the Management of Locally Advanced Head and Neck Cancers? A Contribution to the Controvert. Clinics in Oncology. 2019;4:1664.

[118] Chauhan A., Sehgal S.A., Khurana A., et al. Is Accelerated Radiation Therapy an Answer where Concurrent Chemoradiation is not Feasible for the Management of Locally Advanced Head and Neck Cancers? A Contribution to the Controvert // Clinics in Oncology. 2019. Vol. 4. P. 1664.

[119] LiuY, Kou C, Bai W, et al. Altered fractionation radiotherapy with or without chemotherapy in the treatment of head and neck cancer: a network meta-analysis. Onco Targets Ther. 2018;11:5465–5483. doi: 10.2147/OTT.S172018

[120] Liu Y, Kou C, Bai W., et al. Altered fractionation radiotherapy with or without chemotherapy in the treatment of head and neck cancer: a network meta-analysis // Onco Targets Ther. 2018. Vol. 11. P. 5465–5483. doi: 10.2147/OTT.S172018

[121] Budach V, Cho CH, Sedlmaier B, et al. Five years’ results of the German ARO 04-01 trial of concurrent 72Gy hyperfractionated accelerated radiation therapy (HART) plus once weekly cisplatinum/5-FU versus mitomycin C/5-FU in stage IV head and neck cancer. J Clin Oncol. 2012;30(Suppl 15):5512. doi: 10.1200/jco.2012.30.15_suppl.5512

[122] Budach V., Cho C.H., Sedlmaier B., et al. Five years’ results of the German ARO 04-01 trial of concurrent 72Gy hyperfractionated accelerated radiation therapy (HART) plus once weekly cisplatinum/5-FU versus mitomycin C/5-FU in stage IV head and neck cancer // J Clin Oncol. 2012. Vol. 30, Suppl 15. P. 5512. doi: 10.1200/jco.2012.30.15_suppl.5512

[123] Rades D, Zwaan I, Soror T, et al. Chemoradiation with Cisplatin vs. Carboplatin for Squamous Cell Carcinoma of the Head and Neck (SCCHN). Cancers. 2023;15(13):3278. doi: 10.3390/cancers15133278

[124] Rades D., Zwaan I., Soror T., et al. Chemoradiation with Cisplatin vs. Carboplatin for Squamous Cell Carcinoma of the Head and Neck (SCCHN) // Cancers. 2023. Vol. 15, N. 13. P. 3278. doi: 10.3390/cancers15133278

[125] Iocca O, Farcomeni A, Di Rocco A, et al. Locally advanced squamous cell carcinoma of the head and neck: A systematic review and bayesian network meta-analysis of the currently available treatment options. Oral Oncol. 2018;80:40–51. doi: 10.1016/j.oraloncology.2018.03.001

[126] Iocca O., Farcomeni A., Di Rocco A., et al. Locally advanced squamous cell carcinoma of the head and neck: A systematic review and bayesian network meta-analysis of the currently available treatment options // Oral Oncology. 2018. Vol. 80. P. 40–51. doi: 10.1016/j.oraloncology.2018.03.001

[127] Sanderson RJ, Ironside JA. Squamous cell carcinomas of the head and neck BMJ. 2002;325(7368):822–827. doi: 10.1136/bmj.325.7368.822

[128] Sanderson R.J., Ironside J.A. Squamous cell carcinomas of the head and neck // BMJ. 2002. Vol. 325, N. 7368. P. 822–827. doi: 10.1136/bmj.325.7368.822

[129] Denittis AS, Machtay M, Rosenthal DI, et al. Advanced oropharyngeal carcinoma treated with surgery and radiotherapy: oncologic outcome and functional assessment. Am J Otolaryngol. 2001;22(5):329–335. doi: 10.1053/ajot.2001.26492

[130] De Nittis A.S., Machtay M., Rosenthal D.I., et al. Advanced oropharyngeal carcinoma treated with surgery and radiotherapy: oncologic outcome and functional assessment. Am J Otolaryngol. 2001. Vol. 22, N. 5. P. 329–335. doi: 10.1053/ajot.2001.26492

[131] Podvyaznikov SO, Byakhov MJ. Experience of taxol application in chemotherapy of head and neck squamous cell carcinoma. Modern Oncology. 2002;4(3):126–130. EDN: XIQBNN

[132] Подвязников С.О., Бяхов М.Ю. Опыт применения таксола в химиотерапии плоскоклеточного рака головы и шеи. Современная онкология. 2002. Т. 4. № 3. С. 126–130. EDN: XIQBNN

[133] Gladilina IA. Radiosensitization in radiation therapy of malignant tumors. Effective pharmacotherapy. Oncology, Hematology and Radiology. N.N. Blokhin Russian Oncology Research Center RAMS. 2011;(22):46–53. (In Russ). EDN: SGIALB

[134] Гладилина И.А. Радиосенсибилизация в лучевой терапии злокачественных новообразований // Эффективная фармакотерапия. Онкология, Гематология и Радиология. РОНЦ им. Н.Н. Блохина РАМН. 2011, № 22. С. 46–53. EDN: SGIALB

[135] Artamonova EV, Maznyuk LV. Skin toxicity of EGFR blockers (according to clinical studies of cetuximab). Effective pharmacotherapy. Oncology, Hematology and Radiology. NN. Blokhin Russian Oncology Research Center RAMS. 2012;(34):30–35. (In Russ). EDN: SJWIVL

[136] Артамонова Е.В., Мазнюк Л.В. Кожная токсичность блокаторов EGFR (по данным клинических исследований цетуксимаба) // Эффективная фармакотерапия. Онкология, Гематология и Радиология. РОНЦ им. Н.Н. Блохина РАМН. 2012, № 34. С. 30–35. EDN: SJWIVL

[137] Lee B. Head and neck cancer: treatment & management. head and neck cancers [Updated 24 July 2024]. Available from: https://www.cancertherapyadvisor.com/ddi/head-and-neck-cancer-treatment/

[138] Lee B. Head and neck cancer: treatment & management. head and neck cancers [Updated 24 July 2024]. Доступ по ссылке: https://www.cancertherapyadvisor.com/ddi/head-and-neck-cancer-treatment/

[139] Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2006;354:567–578. doi: 10.1056/NEJMoa053422

[140] Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck // N Engl J Med. 2006. Vol. 354. P. 567–578. doi: 10.1056/NEJMoa053422

[141] Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–28. doi: 10.1016/S1470-2045(09)70311-0 Erratum in: Lancet Oncol. 2010;11(1):14.

[142] Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival // Lancet Oncol. 2010. Vol. 11. N. 1. P. 21–28. doi: 10.1016/S1470-2045(09)70311-0 Erratum in: Lancet Oncol. 2010;11(1):14.

[143] Bonner JA, Giralt J, Harari P, et al. Cetuximab prolongs survival in patients with locally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol. 2004;22(14S):5507.

[144] Bonner J.A., Giralt J., Harari P., et al. Cetuximab prolongs survival in patients with locally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab // J Clin Oncol. 2004. Vol. 22, Suppl. 14. P. 5507.

[145] Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–11127. doi: 10.1056/NEJMoa0802656

[146] Vermorken J.B., Mesia R., Rivera F., et al. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer // N Engl J Med. 2008. Vol. 359, N. 11. P. 1116-11127. doi: 10.1056/NEJMoa0802656

[147] Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25(16):2171–2177. doi: 10.1200/JCO.2006.06.7447

[148] Vermorken J.B., Trigo J, Hitt R., et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy // J Clin Oncol. 2007. Vol. 25, N. 16. P. 2171-2177. doi: 10.1200/JCO.2006.06.7447

[149] Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23(24):5578–5587. doi: 10.1200/JCO.2005.07.120

[150] Herbst R.S., Arquette M., Shin D.M., et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck // J Clin Oncol. 2005. Vol. 23, N. 24. P. 5578–5587. doi: 10.1200/JCO.2005.07.120

[151] Hitt R, Mesía R, Lozano A, et al. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer. Oral Oncol. 2022;134:106087. doi: 10.1016/j.oraloncology.2022

[152] Hitt R., Mesía R., Lozano A., et al. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer // Oral Oncol. 2022. Vol. 134. P. 106087. doi: 10.1016/j.oraloncology.2022.106087

[153] Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck. carcinoma: RTOG 0522. J Clin Oncol. 2014;32(27):2940–2950. doi: 10.1200/JCO.2013.53.5633

[154] Ang K.K., Zhang Q., Rosenthal D.I., et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck. carcinoma: RTOG 0522 // J Clin Oncol. 2014. Vol. 32, N. 27. P. 2940–2950. doi: 10.1200/JCO.2013.53.5633

[155] Garden AS, Morrison WH, Rosenthal DI, et al. Target coverage for head and neck cancers treated with IMRT: review of clinical experiences. Semin Radiat Oncol 2004;14(2):103–9. doi: 10.1053/j.semradonc.2003.12.004

[156] Garden A.S., Morrison W.H., Rosenthal D.I., et al. Target coverage for head and neck cancers treated with IMRT: review of clinical experiences // Semin Radiat Oncol 2004. Vol. 14, N. 2. P. 103–109. doi: 10.1053/j.semradonc.2003.12.004

[157] Chubenko VA. Complications of targeted therapy. Prakticheskaia onkologia. 2010;11(3):192–202. (In Russ).

[158] Чубенко В.А. Осложнения таргетной терапии // Практическая онкология. 2010. Т. 11, № 3. С. 192–202.

[159] Healthyni CS, Subroto T, Megantara S, et al. Potential use of lapatinib in the treatment of head and neck squamous cell carcinoma (Review). World Academy of Sciences Journal. 2022;4(5):35. doi: 10.3892/wasj.2022.170

[160] Healthyni C.S., Subroto T., Megantara S., et al. Potential use of lapatinib in the treatment of head and neck squamous cell carcinoma (Review) // World Academy of Sciences Journal. 2022. Vol. 4, N. 5. P. 35. doi: 10.3892/wasj.2022.170

[161] Benasso M, Corvò R, Ponzanelli A, et al. Alternating gemcitabine and cisplatin with gemcitabine and radiation in stage IV squamous cell carcinoma of the head and neck. Annals of Oncology. 2004;15:646–652. doi: 10.1093/annonc/mdh138

[162] Benasso M., Corvò R., Ponzanelli A., et al. Alternating gemcitabine and cisplatin with gemcitabine and radiation in stage IV squamous cell carcinoma of the head and neck // Annals of Oncology. 2004. Vol. 15. P. 646–652. doi: 10.1093/annonc/mdh138

[163] Kurpeshev OK, Tsyb AF, Mardynskiy YuS, Berdov BA. The mechanism of development and ways of overcoming the chemoresistance of tumors. Part 1. Multidrug resistance of tumor cells. Russian Journal of Oncology. 2002;4:48–51. (In Russ). EDN: TLEYDD

[164] Курпешев О.К., Цыб А.Ф., Мардынский Ю.С., Бердов Б.А. Механизмы развития и пути преодоления химиорезистентности опухолей. Часть 1. Множественная лекарственная устойчивость опухолевых клеток // Российский онкологический журнал. 2002. № 4. С. 48–51. EDN: TLEYDD

[165] Kurpeshev OK, Tsyb AF, Mardinsky YuS, Berdov BA. Mechanisms of development and ways to overcome chemoresistance of tumors. Part 2. The role of the relationship between the stroma and tumor parenchyma in the effectiveness of chemotherapy. Russian Journal of Oncology. 2003;1:50–54. (In Russ). EDN: OKJFQP

[166] Курпешев О.К., Цыб А.Ф., Мардынский Ю.С., Бердов Б.А. Механизмы развития и пути преодоления химиорезистентности опухолей. Часть 2. Роль взаимоотношений стромы и паренхимы опухоли в эффективности химиотерапии // Российский онкологический журнал. 2003. № 1. С. 50–52. EDN: OKJFQP

[167] Kurpeshev OK, Tsyb AF, Mardynskiy YuS, Berdov BA. The mechanism of development and ways of overcoming the chemoresistance of tumors. Part 3. Possible ways to overcome tumor chemoresistance. Russian Journal of Oncology. 2003;2:50–53. (In Russ). EDN: OKJFWJ

[168] Курпешев О.К., Цыб А.Ф., Мардынский Ю.С., Бердов Б.А. Механизм развития и пути преодоления химиорезистентности опухолей. Часть 3. Возможные пути преодоления химиорезистентности опухолей // Российский Онкологический журнал. 2003. № 2. С. 50–53. EDN: OKJFWJ

[169] Stavrovskaya AA, Gens GP. Some new aspects of studies of multidrug resistance of tumor cells. Advances in molecular oncology. 2014;1(1):5–11. doi: 10.17650/2313-805X.2014.1.1.5-11

[170] Ставровская А.А., Генс Г.П. Некоторые новые аспекты исследований множественной лекарственной устойчивости опухолевых клеток // Успехи молекулярной онкологии. 2014. Т. 1, № 1. С. 5–11. doi: 10.17650/2313-805X.2014.1.1.5-11

[171] Emran TB, Shahriar A, Mahmud AR, et al. Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches. Front Oncol. 2022; 12:891652. doi: 10.3389/fonc.2022.891652

[172] Emran T.B., Shahriar A., Mahmud A.R., et al. Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches // Front Oncol. 2022. Vol. 12. P. 891652. doi: 10.3389/fonc.2022.891652

[173] Zhou LY, Zhou LY. Research Advance of BCR-ABL Mutation and the Efficacy of Second and Third Generation TKI in Chronic Myeloid Leukemia–Review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023;31(2):585–588. doi: 10.19746/j.cnki.issn.1009-2137.2023.02.040

[174] Zhou L.Y., Zhou L.Y. Research Advance of BCR-ABL Mutation and the Efficacy of Second and Third Generation TKI in Chronic Myeloid Leukemia—Review // Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023. Vol. 31. N. 2. P. 585–588. doi: 10.19746/j.cnki.issn.1009-2137.2023.02.040

RIGHTS & PERMISSIONS

Eco-Vector